Acemannan is a complex carbohydrate extracted from the aloe vera plant. It is a polysaccharide composed of mannose units linked together by beta-1,4 glycosidic bonds. It has been studied for its potential health benefits, including wound healing, immune modulation, and anti-inflammatory properties. Acemannan is thought to work by stimulating the immune system and promoting the production of cytokines, which are signaling molecules that help regulate immune responses. Research has shown that acemannan may be effective in treating a variety of conditions, including skin ulcers, burns, and infections. It is also being investigated for its potential role in cancer treatment and prevention.'
acemannan: prepared from extract of the Aloe barbadensis plant [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Aloe | genus | A plant genus of the family Xanthorrhoeaceae which is used medicinally. It contains anthraquinone glycosides such as aloin-emodin or aloe-emodin (EMODIN).[MeSH] | Asphodelaceae | [no description available] |
| ID Source | ID |
|---|---|
| PubMed CID | 72041 |
| SCHEMBL ID | 15532050 |
| MeSH ID | M0162908 |
| Synonym |
|---|
| 110865-83-3 |
| acemananan [inn-spanish] |
| acemannanan |
| alpha-d-galacto-beta-d-mannan, (1-4),(1-6)-, acetate |
| acemannanum [inn-latin] |
| aloe vera mucilage |
| 110042-95-0 |
| acemannan |
| A802474 |
| (2s,3s,4r,5s,6s)-6-[[(2r,3r,4r,5s,6r)-6-[[(2r,3s,4r,5s,6r)-5-acetamido-6-[[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[[(2r,3r,4r,5s,6s)-4-acetyloxy-5-hydroxy-2-(hydroxymethyl)-6-methoxy-3-oxanyl]oxy]-5-hydroxy-2-(hydroxymethyl)-3-oxa |
| (2s,3s,4r,5s,6s)-6-[(2r,3r,4r,5s,6r)-6-[(2r,3s,4r,5s,6r)-5-acetamido-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6r)-4-acetyloxy-6-[(2r,3r,4r,5s,6s)-4-acetyloxy-2-(hydroxymethyl)-6-methoxy-5-oxidanyl-oxan-3-yl]oxy-2-(hydroxymethyl)-5-oxidanyl-oxan-3-y |
| snow & sun sports gel |
| carraklenz wound & skin cleanser |
| uz29e6l2x8 , |
| unii-uz29e6l2x8 |
| acemannanum |
| acemananan |
| SCHEMBL15532050 |
| DTXSID00149125 , |
| cello gel |
| acemannan aloe vera (1400000 mw) |
| acemannan aloe vera (1300000 mw) |
| acemannan (aloe vera) |
| 115426-79-4 |
| 115426-79-4 (free base) |
| (2s,3s,4s,5s,6s)-6-[(2r,3r,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-5-acetamido-6 -[(2r,3r,4s,5s,6r)-4-acetylox |
| aloe acetylated mannan polysaccharide 1300 kda mw |
| dtxcid1071616 |
| acemanan |
| acemannan (mart.) |
| AKOS040750050 |
Acemannan is a polydispersed beta-(1,4)-linked acetylated mannan with antiviral properties. Acemannan was found to be a safe and predictable biomaterial for GBR.
Acemannan has various medicinal properties like osteogenic, anti-inflammatory, and antibacterial, which accelerate healing of lesions. Acemannan also has pulpal biocompatibility and promotes soft tissue organization.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Acemannan has various medicinal properties like osteogenic, anti-inflammatory, and antibacterial, which accelerate healing of lesions." | ( Acemannan, an extracted polysaccharide from Aloe vera: A literature review. Castro-Ríos, R; Chávez-Montes, A; González-Horta, A; Lara-Arias, J; Sierra-García, GD, 2014) | 2.57 |
| "Acemannan has been previously reported as a direct pulp-capping agent in animal study. " | ( Clinical, radiographic, and histologic analysis of the effects of acemannan used in direct pulp capping of human primary teeth: short-term outcomes. Banlunara, W; Sangvanich, P; Songsiripradubboon, S; Thunyakitpisal, P; Trairatvorakul, C, 2016) | 2.11 |
| "Acemannan also has pulpal biocompatibility and promotes soft tissue organization." | ( Acemannan, an extracted product from Aloe vera, stimulates dental pulp cell proliferation, differentiation, mineralization, and dentin formation. Banlunara, W; Jittapiromsak, N; Sahawat, D; Sangvanich, P; Thunyakitpisal, P, 2010) | 2.52 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Acemannan did not enhance lymphocyte response to syngeneic antigens in the mixed lymphocyte culture (MLC) but importantly increased alloantigenic response in a dose-response fashion (2.6 x 10(-7) - 2.6 x 10(-9)M)." | ( Enhancement of allo-responsiveness of human lymphocytes by acemannan (Carrisyn). Helderman, JH; Womble, D, 1988) | 1.24 |
The acemannan-treated group exhibited a complete homogeneous calcified dentin bridge and good pulp tissue organization. Neither was detected in the calcium hydroxide-treated and sham groups.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The acemannan-treated group also exhibited a complete homogeneous calcified dentin bridge and good pulp tissue organization, whereas neither was detected in the calcium hydroxide-treated and sham groups." | ( Acemannan, an extracted product from Aloe vera, stimulates dental pulp cell proliferation, differentiation, mineralization, and dentin formation. Banlunara, W; Jittapiromsak, N; Sahawat, D; Sangvanich, P; Thunyakitpisal, P, 2010) | 2.28 |
| "Acemannan treatments were continued monthly for one year." | ( The effect of Acemannan Immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas. Ford, CR; Greenlee, PG; King, GK; McAnalley, BH; Pierce, KR; Tizard, IR; Yates, KM, ) | 1.21 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " This review summarises and explains the current pharmacodynamic paradigm in the context of acemannan in topical, oral, and intravenous applications." | ( Pharmacodynamics of Aloe vera and acemannan in therapeutic applications for skin, digestion, and immunomodulation. Sadgrove, NJ; Simmonds, MSJ, 2021) | 1.12 |
Acemannan (ACE-M) is a long-chained, polydispersed, beta-(1,4)-acetylated mannan. Acemannan was tested in combination with azidothymidine (AZT) and acyclovir (ACY) in vitro.
| Excerpt | Reference | Relevance |
|---|---|---|
| "The antiviral effects of selected combinations between acemannan (ACE-M), a long-chained, polydispersed, beta-(1,4)-acetylated mannan, were tested in combination with azidothymidine (AZT) and acyclovir (ACY) in vitro." | ( In vitro evaluation of the synergistic antiviral effects of acemannan in combination with azidothymidine and acyclovir. Carpenter, RH; Kahlon, JB; Kemp, MC; McAnalley, BH; Shannon, WM; Yawei, N, 1991) | 0.77 |
| "Eight dogs and five cats with histopathologically confirmed fibrosarcomas were treated with Acemannan Immunostimulanta in combination with surgery and radiation therapy." | ( The effect of Acemannan Immunostimulant in combination with surgery and radiation therapy on spontaneous canine and feline fibrosarcomas. Ford, CR; Greenlee, PG; King, GK; McAnalley, BH; Pierce, KR; Tizard, IR; Yates, KM, ) | 0.71 |
| Excerpt | Relevance | Reference |
|---|---|---|
| " Acemannan did not enhance lymphocyte response to syngeneic antigens in the mixed lymphocyte culture (MLC) but importantly increased alloantigenic response in a dose-response fashion (2." | ( Enhancement of allo-responsiveness of human lymphocytes by acemannan (Carrisyn). Helderman, JH; Womble, D, 1988) | 1.43 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (1.54) | 18.7374 |
| 1990's | 24 (36.92) | 18.2507 |
| 2000's | 5 (7.69) | 29.6817 |
| 2010's | 24 (36.92) | 24.3611 |
| 2020's | 11 (16.92) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (45.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 10 (14.71%) | 5.53% |
| Reviews | 9 (13.24%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 49 (72.06%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| CelAgace™ OraRinse (CAOR) Pilot Clinical Study for Management of Candidiasis Associated With Grade 0-II Mucositis [NCT03250923] | Phase 1/Phase 2 | 15 participants (Anticipated) | Interventional | 2023-09-30 | Not yet recruiting | ||
| The Effect of RadiaAce Gel Versus Biafine in the Prevention and Treatment of Radiation Dermatitis in Breast Cancer Patients [NCT04481802] | 120 participants (Anticipated) | Interventional | 2021-07-14 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||